Liver International ISSN 1478-3223

REVIEW ARTICLE

Treatment of hepatitis C virus genotype 3-infection Stanislas Pol, Ana€ıs Vallet-Pichard and Marion Corouge ^pital Cochin, INSERM U-1016, Institut Cochin, Paris, France Universit e Paris Descartes, APHP, Unit e d’H epatologie, Ho

Keywords cirrhosis – combination therapy – directacting antiviral – hepatitis C virus – polymerase inhibitor – protease inhibitor – replication complex inhibitor Abbreviations DAAs, direct-acting antiviral drugs; EVR, early virological response; HCV, hepatitis C virus; PEG-IFN, pegylated interferon; RBV, ribavirin; RVR, rapid viral response; SOC, standard of care; SVR, sustained virological response. Correspondence: Pr. Stanislas Pol, MD, PhD, Unit e ^pital Cochin, 7 rue du d’H epatologie, Ho faubourg Saint Jacques, 75679 Paris Cedex 14, France Tel: +33 1 58 41 30 01 Fax: +33 1 58 41 30 15 e-mail: [email protected] DOI:10.1111/liv.12405

Abstract The treatment of hepatitis C virus (HCV) infection with pegylated interferon (PEG-IFN) alfa and ribavirin (800 mg daily) (RBV) is the standard of care (SOC) for hepatitis C virus genotype 3-infection leading to a sustained virological response (SVR) in around 65% of patients. A better understanding of the HCV life-cycle has recently resulted in the development of several potential direct-acting antiviral drugs (DAAs) targeting viral proteins (NS3/ 4A protease, NS5B nucleos(t)idic and non-nucleos(t)idic polymerase, NS5A viral replication complex). First generation protease inhibitors in combination with PEG-IFN/RBV are not efficient in genotype 3-infected patients. The combination of PEG-IFN/RBV with Daclatasvir, a NS5A inhibitor for 12–24 weeks results in a SVR in around 75% while the triple combination of PEG-IFN/RBV with the oral nucleotidic polymerase inhibitor Sofosbuvir (GS-7977) for 12 weeks in na€ıve patients results in a SVR in more than 95%. The results of the first oral combination of Sofosbuvir and RBV for 12 weeks in genotype 3-infected patients have been rather disappointing with a slightly lower SVR than after 24 weeks of PEG-IFN: around 60%, and only 30% in patients with cirrhosis. Extending treatment from 12 to 16 weeks in treatment experienced patients doubled the SVR rate and an 80% SVR rate is expected by extending treatment to 24 weeks. The best oral combination of new DAAs is probably the combination of Sofosbuvir and a NS5A inhibitor (Daclatasvir, Ledipasvir…) for 24 weeks, which resulted in a 100% SVR rate in a limited series. The use of cyclophilin inhibitors, a host-targeted antiviral, in association with DAAs and/or RBV may also be of interest. The oral combination of new DAAs (dual or triple combination of different antivirals) or of DAAs and host targets such as cyclophilin will probably become the SOC for genotype 3-infected treatment-na€ıve or -experienced patients.

Although the global distribution of hepatitis C virus (HCV) genotypes differs across geographical areas, genotype 3 is common worldwide, accounting for around 30% of infected patients in Northern Europe and Asia. Compared with other genotypes, genotype 3infection, which is highly prevalent in South East Asia and in drug users, has been associated with an increased risk of the progression of fibrosis, steatosis and the development of hepatocellular carcinoma in patients with cirrhosis (1–4). Treatment of chronic hepatitis C with pegylated interferon alfa (PEG-IFN) and ribavirin (RBV) for 24 weeks results in a sustained viral response (SVR), corresponding to a complete virological recovery, in around 70% of patients with HCV-genotype 3 compared with around 80% in those with genotype 2 and 45% in those with genotype 1 before the addition of protease inhibitors (5–10). A better understanding of the HCV life-cycle and the characterization of viral enzymes that are potential antiviral targets (11) have led to the development of a

18

number of potential new direct-acting antiviral drugs (DAAs) targeted against viral proteins (12). Several new non-DAA agents, which may be associated with DAAs are also under development, e.g. new interferons, cyclophilin inhibitors and vaccine therapy (13, 14). The different classes of DAA and non-DAA new agents are summarized in Figure 1. Combining direct-acting or host-targeted antivirals with PEG-IFN may enhance virological responses and/or allow shorter treatment durations in genotype 3 patients, even if the currently approved NS3 protease inhibitors (Telaprevir and Boceprevir) are not indicated. Standard of care in 2013

Twenty-four weeks of PEG-IFN and RBV, the current SOC for the treatment of HCV genotype 2- or 3-infection, results in a SVR in 70–80% of patients (5–10). A meta-analysis of studies with PEG-IFN and RBV reported 74% and 68% SVR rates in genotypes 2- and 3-infection respectively (10). Liver International (2014) © 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd

Pol et al.

Treatment of HCV genotype 3

Viral targets C

E1

E2

p7

NS2

NS3

NS3 The NS3/4A serine protease

Boceprevir Telaprevir ABT-450/r, ACH-1625 Asunaprevir, TMC-435 (Simeprevir), BI-201335 Danoprevir/r, GS-9451 MK-5172 *

NS4A

Host targets NS4B

NS5A

NS5A

NS5B

NS5B

Multifunctional phosphoprotein, RNA-dependent RNA component of the HCV-RNA polymerase replication complex

Daclatasvir GS-5885 ABT-267 PPI-668 MK

Nucleos(t)ide analogue GS-7977 (Sofosbuvir), Mericitabine, IDX-184 Non-nucleoside analogue BI-207127, ABT-333 ABT-072, BMS-791325 Tegobuvir, Setrobuvir VX-222, Filibuvir

Cyclophilin A Host protein interacting with NS5A and the NS5B

Alisporivir SCY-635

Fig. 1. Different classes of DAAs.

The recent European Association for the Study of the Liver (EASL) Clinical Practice Guidelines recommended a dose of 15 mg/kg/day in genotype 1- or 4- patients and a fixed dose of 800 mg/day in genotype 2- or 3patients (9): weight-based (800–1400 mg/day) compared with flat-dose (800 mg/day) RBV does not increase the SVR rate (15). Baseline viral load is one of the determinants of outcome. SVR rates are consistently higher in patients with low baseline HCV RNA levels, usually defined as 2 log10 decrease at week 12, randomized 188 patients either to stop at week 24 (n = 95) or to continue PEG-IFN until week 48 (n = 93) (19). Per protocol analysis suggested a non-significant trend towards an improvement in SVR rates [63% vs. 52% with an odds ratio of 0.63 (CI 95%: 0.35–1.16)]. DAAs with pegylated interferon NS3/NS4A protease inhibitors (PI)

Most first-generation NS3/NS4A protease inhibitors specifically target HCV genotype 1 and are not very potent against genotype 3 (20). Second-generation NS3/NS4A protease inhibitors have limited effect on genotype 3 in association with PEG-IFN, although they are usually considered to have a ‘pangenotypic’ antiviral activity. For example, Simeprevir, which might be interesting because of its broader antiviral spectrum (it inhibits viral replication of genotypes 1, 2, 4, 5 and 6 in vitro) has no antiviral potency against genotype 3 (21).

19

Pol et al.

Treatment of HCV genotype 3

NS5A inhibitors

Daclatasvir (DCV, BMS-790052), the first-in class NS5A inhibitor, is a potent and highly selective NS5A replication complex inhibitor with broad genotypic coverage (genotypes 1–5) and a pharmacokinetic profile that allows once-daily dosing (22). Daclatasvir in combination with PEG-IFN for 24 to 48 weeks resulted in a SVR rate of around 75% in genotype 1 patients (23). A randomized, double-blind, phase 2b study assessed whether a combination of Daclatasvir and SOC improved treatment efficacy and shortened the duration of therapy in genotypes 2- and 3. Patients received 12 or 16 weeks of Daclatasvir (60 mg once daily) or 24 weeks of placebo, combined with standard PEG-IFN. Treatment was extended to 24 weeks (12 additional weeks of PEG-IFN) in Daclatasvir recipients who did not have an early virological response (EVR). The primary endpoint was the SVR 24 weeks after the end of treatment (SVR24) (24). In patients with genotype 3, end-of-treatment responses were numerically higher in the Daclatasvir groups (89–96%) than with PEG-IFN and Ribavirin (78%). SVR24 rates were 69.2%, 66.7% and 59.3% in the Daclatasvir 12-week and 16-week groups and in the placebo arms respectively. Differences in SVR24 between genotypes 2 (83.3%, 82.6% and 62.5%, respectively) and 3 were largely because of the more frequent post-treatment relapse with the latter. SVR24 was less frequent in patients with genotype 3 and cirrhosis (45%) than in those without cirrhosis (74%) in the combined Daclatasvir arms and in the placebo arm (43% vs. 65% respectively). Relapse rates were slightly higher in patients with cirrhosis, non-CC IL28B genotypes, high HCV RNA levels at baseline and high BMI while baseline Daclatasvir resistance-associated NS5A polymorphisms only partially contributed to relapse. Thus, addition of Daclatasvir to PEG-IFN provided more rapid suppression of serum HCV RNA levels than PEG-IFN and Ribavirin, followed by similar or greater rates of SVR with shorter (12 or 16 weeks) durations of therapy, which is beneficial for both patients and healthcare providers. Other NS5A inhibitors are under development and have been associated in oral combinations with interesting results (ABT-267 and GS-5885) (see below) while others are in rapid development (MK-8742, GSK2336805, PPI-668). NS5B polymerase inhibitors

Two different classes of polymerase inhibitors are currently being developed: nucleos(t)idic (Sofosbuvir/GS7977 and Mericitabine) and non-nucleosidic (ABT-333, VX-222, BI-207127, BMS-791325) inhibitors which may or may not be combined interferon. The combination of Mericitabine with PEG-IFN in genotype 1 patients resulted in a SVR of less than 60%

20

(25). On the other hand, the combination of Sofosbuvir (400 mg QD) and PEG-IFN and Ribavirin for 12 to 24 weeks in genotypes 1-, 4-, 5- and 6 resulted in a SVR12 rate of more than 90% with a fair safety profile. Similar results have been achieved in na€ıve genotype 2 and 3 patients. In the ELECTRON study a combination of Sofosbuvir (400 mg QD) and RBV for 12 weeks plus PEG-IFN for 4, 8 or 12 weeks in genotypes 2-, and 3 patients (n = 10 by arm) resulted in a 100% SVR12 rate (26). In an open-label cohort of patients with genotypes 2- or 3- without cirrhosis who received Sofosbuvir (400 mg) and PEG-IFN and Ribavirin for 12 weeks, 23/ 25 (92%) achieved SVR12 (PROTON study) (27). All of these studies of second generation-DAAs in combination with PEG-IFN and Ribavirin usually result in higher antiviral potency with a better safety profile than those reported with the SOC. The limits to these studies are mainly the combination with IFN and the numerous PEG-IFN and Ribavirin-associated adverse events rather than the duration of the treatment. New combinations without IFN with greater antiviral potency and safety/tolerance are expected. Interferon free oral DAA-combinations

By targeting various steps of viral replication a combination of several DAA agents could induce viral suppression, prevent the emergence of viral resistance and allow eradication of HCV in interferon-free regimens. The most promising results of oral combinations have been reported with the combinations of Daclatasvir and Asunaprevir in genotype 1b-patients (28) or with Sofosbuvir in genotypes 1-, 2- and 3- patients (26, 27, 29– 36). Sofosbuvir and ribavirin

The ELECTRON study combining Sofosbuvir/GS-7977 and RBV for 12 weeks (compared with Sofosbuvir/GS7977 and PEG-IFN) resulted in a 100% SVR rate in na€ıve genotype 2- and 3-patients without cirrhosis (10 patients per arm) while 12-weeks of monotherapy wtih Sofosbuvir, reducing the dose of RBV (800 mg) or decreasing treatment to 8 weeks reduced the SVR rate (60%, 60% and 67% respectively) (26). Finally, the 12week Sofosbuvir/GS-7977 and RBV combination in 25 non-na€ıve patients resulted in a SVR rate of 68% (26). The results of phase III studies in genotype 3patients with cirrhosis were poor. In the POSITRON study, 278 genotype 2 and 3 na€ıve patients received 12 weeks of Sofosbuvir/GS-7977 (400 mg QD) and RBV (n = 207) or placebo (n = 71) (16% with cirrhosis, 51% genotype 2 and 49% genotype 3). SVR12 rates were 78% (compared with 0% in the placebo arm) in the overall population (93% in genotype 2 and 61% in genotype 3): 61% in patients without cirrhosis vs. 21% in genotype 3 patients with cirrhosis (30). In the FISSION study, 499 genotype 2 and 3 na€ıve Liver International (2014) © 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd

Pol et al.

Treatment of HCV genotype 3

patients received a combination of Sofosbuvir/GS-7977 and RBV (1000–1200 mg/day) for 12 weeks (n = 256) or SOC PEG-IFN and Ribavirin for 24 weeks (n = 243) (20% with cirrhosis, 28% with genotype 2 and 72% with genotype 3). Although the SVR12 rates were similar with the new oral combination and with PEG-IFN (67%) they were different for genotype 2 (97% vs. 78%) and not different for genotype 3 (56% vs. 63%) or patients with cirrhosis (34% vs. 30%) (31). Extending therapy from 12 to 16 weeks in the FUSION trial (32) in PEG-IFN-experienced genotypes 2- and 3- patients, resulted in: (i) an increase in the SVR12 from 50 to 73% (P < 0.001); (ii) doubling the SVR12 rate in genotype 3- patients (30% vs. 62%, P < 0.001) and (iii) a marked increase in the SVR12 from 19 to 61% in genotype 3 patients with cirrhosis by reducing the high rate of relapse. These disappointing results in genotype 3 patients with cirrhosis (compared with the excellent results in genotype 2- patients whatever the stage of fibrosis) explains why treatment was extended from 12 to 24 weeks with the Sofosbuvir/RBV combination in genotype 3 patients from the European VALENCE study in February 2013. The SVR12 rate in genotype 3infected patients was 94% and 92% in naı¨ve non cirrhotic and cirrhotic patients, respectively and 87% and 60% in experienced non cirrhotic and cirrhotic patients, respectively (Zeuzem S et al. American Association for the Study of Liver Disease, Washington 2013).

in the Lonestar Study (34). Similar results were reported in genotype 1 PEG-IFN experienced patients in whom the SVR12 rate after 24 weeks of Daclatasvir plus Sofosbuvir with (n = 20) or without (n = 21) RBV was 95% and 100% respectively (35). Daclatasvir was studied in combination with Sofosbuvir in the first study evaluating the combination of an NS5A inhibitor and a nucleotide NS5B inhibitor in an interferon-free regimen (36). Treatment-na€ıve patients with HCV genotypes 1, 2 or 3 received Daclatasvir (60 mg QD) plus Sofosbuvir (400 mg QD), with or without a one week lead-in of Sofosbuvir and with or without RBV for 24 weeks (36). In patients with HCV genotypes 2 or 3, 94–100% (15/16 and 14/14) of patients treated with the Daclatasvir plus Sofosbuvir combination, and 86% (12/14) of those receiving the Daclatasvir/Sofosbuvir/RBV combination had undetectable HCV RNA at Week 24 (end of treatment). 88–100% (14/16 and 14/14) of patients treated with the Daclatasvir plus Sofosbuvir combination, and 86% (12/14; two patients were lost to follow-up) of those receiving the Daclatasvir/Sofosbuvir/RBV combination achieved SVR4 and SVR12. Thus, with an all-oral combination of Daclatasvir plus Sofosbuvir, SVR12 rates of >95% were achieved in HCV genotypes 2 and 3. The Sofosbuvir lead-in phase or the addition of RBV did not affect virological response, and the latter increased the frequency of anaemia (which was absent in the RBV-free arms).

Sofosbuvir and other inhibitors

Other DAA combinations

Sofosbuvir plus Simeprevir (Cosmos Study) (33) or Sofosbuvir plus Ledipasvir in experienced genotype 1 patients and protease inhibitor-experienced patients, respectively, resulted in a SVR12 rate of more than 95%

Interesting results have been reported in genotype 1patients without cirrhosis who received quadruple or quintuple combination ABT-450 boosted by Ritonavir, the ABT-267 NS5A inhibitor, in association or not with the NS5B non-nucleos(t)idic polymerase inhibitor ABT333 and RBV for 8 to 12 weeks. The SVR12 rates were from 87 to 97% in na€ıve patients and 93% in experienced non-responders, including 100% in subtype 1b patients (37). Trials have begun with these combinations in genotypes 2- and 3- patients. Similarly, a combination of Daclatasvir, Asunaprevir and a non-nucleosidic polymerase inhibitor (BMS-791325) resulted in a SVR in 95 to 100% of na€ıve genotype 1 patients. Trials in genotypes 2 and 3 are ongoing (38).

PEG Interferon180µg α2a or 1.5µg α2b /w + Ribavirin (800 mg/d) for 24w.

No SVR ~ 30%

SVR ~ 70% 2013

No therapeutic option

2014 ~ 80%

SOF/PR 12 w. (or 12+12?) SOF/RBV 24 w.

2015

DCV/PR 12 w. SOF/RBV 24 w.

~ 80% ~ 95%

No SVR ~ 20% 20

SOF/DCV or LDV 24w. SOF/LDV 24 w. QUAD ABT or ASV/DCV/I Pol 12 w.

Fig. 2. A time-dependent therapeutic algorithm adapted to the available drugs (Sofosbuvir, Daclatasvir, Ledipasvir, the ABT-450/r, ABT-267, ABT-333 combination or Daclatasvir, Asunaprevir and BMS-791325) and the putative economical constraints in the different geographical areas. At present the standard of care is still the combination of Interferon and Ribavirin.

Liver International (2014) © 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd

New non-DAA host-targeted antiviral agents

In VITAL-1, a phase IIb study na€ıve genotype 2- and 3patients received the cyclophilin inhibitor Alisporivir (600 to 1000 mg/day) with or without PEG-IFN or RBV (800 mg/day) for 24 weeks after a lead-in phase of one week with Alisporivir 600 mg BID. The SVR12 was 81– 83% in Alisporivir-treated patients with or without RBV, 77% with Alisporivir/PEG-IFN and 58% in the PEG-IFN/RBV arm (39). The potential benefit of other host-targeted agents (lambda IFN which appeared to be better tolerated in the Emerge trial in genotype 2- and

21

Pol et al.

Treatment of HCV genotype 3

3- patients or vaccine therapy, entry inhibitors, miRNAs) needs to be demonstrated.

6.

Conclusion

In conclusion, as treatment options have progressed and improved, HCV genotype 3-infection has become the most difficult-to-treat genotype, even if the SOC results in a SVR of 67%. The Daclatasvir/PEG-IFN and Sofosbuvir/RBV combinations result in similar SVR rates with the differences in results in genotypes 2 and 3 explained by robust and similar on-treatment virological responses, but genotype-specific differences in posttreatment relapse. The combination of Sofosbuvir/RBV for 24 weeks or Daclatasvir/PEG-IFN/RBV for 12 weeks will probably increase this rate to 75% and to >95% in the 12 week Sofosbuvir/PEG-IFN combination (at least in PEG-IFN-na€ıve patients; very recent results suggest a 85% SVR rate in genotype 3-infected patients with cirrhosis) (Fig. 2). This impressive result is similar to that obtained with various DAA combinations with Sofosbuvir and NS5A inhibitors for 24 weeks (shorter durations are under evaluation) with a good tolerance.

7.

8.

9. 10.

11. 12. 13.

Disclosure

Financial support: Stanislas Pol has received consulting and lecturing fees from Bristol-Myers Squibb, Boehringer Ingelheim, Janssen, Vertex, Gilead, Roche, ScheringPlough/Merck, Novartis, Abbott, Sanofi and GlaxoSmithKline, and grants from Bristol-Myers Squibb, Gilead, Roche and Merck/Schering Plough. Ana€ıs ValletPichard: oral presentations, national and international congress as auditor, subinvestigator in clinical trials for Bristol-Myers Squibb, Boehringer Ingelheim, Janssen, Vertex, Gilead, Roche, Schering-Plough/Merck, Novartis, Abbott and GlaxoSmithKline. Marion Corouge has no conflict of interest to declare.

14. 15.

16. 17. 18.

References 1. Coppola N, Vatiero LM, Sagnelli E. HCV genotype 2 as a risk factor for reactivation of chronic HCV infection. Gut 2005; 54: 1207. 2. Nkontchou G, Ziol M, Aout M, et al. HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis. J Viral Hepatol 2011; 18: e516–22. 3. Larsen C, Bousquet V, Delarocque-Astagneau E, et al. Hepatitis C virus genotype 3 and the risk of severe liver disease in a large population of drug users in France. J Med Virol 2010; 82: 1647–54. 4. Bochud PY, Cai T, Overbeck K, et al. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. J Hepatol 2009; 51: 655–66. 5. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-

22

19.

20.

21.

22.

2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958–65. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975–82. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346–55. Zeuzem S, Hultcrantz R, Bourliere M, et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004; 40: 993–9. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis C virus infection. J Hepatol 2011; 55: 245–64. Andriulli A, Mangia A, Iacobellis A, et al. Meta-analysis: the outcome of anti-viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis. Aliment Pharmacol Ther 2008; 28: 397–404. Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus. Nat Rev Microbiol 2007; 5: 453–63. Buhler S, Bartenschlager R. New targets for antiviral therapy of chronic hepatitis C. Liver Int 2012; 32(Suppl.): 9– 16. Donnelly RP, Kotenko SV. Interferon-lambda: a new addition to an old family. J Interferon Cytokine Res 2010; 30: 555–64. Flisiak R, Dumont JM, Crabbe R. Cyclophilin inhibitors in hepatitis C viral infection. Expert Opin Investig Drugs 2007; 16: 1345–54. Jacobson IM, Brown RS, Freilich B, et al. Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. Hepatology 2007; 46: 971–81. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399–401. Shiffman ML, Suter F, Bacon BR, et al. Peg-interferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007; 357: 124–34. Di Martino V, Richou C, Cervoni JP, et al. Responseguided peg-interferon plus ribavirin treatment duration in chronic hepatitis C: meta-analyses of randomized, controlled, trials and implications for the future. Hepatology 2011; 54: 789–800. Cheinquer H, Shiffman ML, Zeuzem S, et al. The outcome of 24 vs 48 weeks of peginterferon alfa-2a (40KD) plus ribavirin on sustained virologic response rates in patients infected with genotype 2 or 3 hepatitis C virus who do not achieve a rapid viral response: the N-CORE study. Hepatology 2013; 56(Suppl. 1): 271A. Foster GR, Hezode C, Bronowicki JP, et al. Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections. Gastroenterology 2011; 141: 881–9. Lenz O, Vijgen L, Berke JM, et al. Virologic response and characterisation of HCV genotype 2-6 in patients receiving TMC435 monotherapy (study TMC435-C202). J Hepatol 2013; 58: 445–51. Gao M, Nettles RE, Belema M, et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 2010; 465: 96–100.

Liver International (2014) © 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd

Pol et al.

23. Pol S, Ghalib RH, Rustgi VK, et al. Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial. Lancet Infect Dis 2012; 12: 671–7. 24. Dore GJ, Lawitz E, Hezode C, et al. Daclatasvir combined with peginterferon alfa-2a and ribavirin for 12 or 16 weeks in patients with hepatitis C virus genotype 2 or 3 infection: COMMAND GT 2/3 study. J Hepatol 2012; 58(Suppl. 1): S570–1. 25. Pockros P, Jensen D, Tsai N, et al. SVR-12 among G1/4 treatment-naive patients receiving Mericitabine in combination with PEG-IFN a-2A/RBV: interim analysis from the JUMP-C study. J Hepatol 2012; 56(Suppl. 2): S477–8. 26. Gane EJ, Stedman CA, Hyland RH, et al. Nucleotide polymerase inhibitor Sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013; 368: 34–44. 27. Lawitz E, Lalezari JP, Hassanein T, et al. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-na€ıve patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis 2013; 13: 401–08. 28. Lok AS, Gardiner DF, Lawitz E, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 2012; 366: 216–24. 29. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Eng J Med 2013; 368: 1878–87. 30. Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368: 1867–77. 31. Gane E, Lawitz E, Rodriguez-Torres M, et al. Phase 3 randomized controlled trial of all oral treatment with Sofosbuvir + ribavirin for 12 weeks compared to 24 weeks of Peg + ribavirin in treatment-na€ıve GT 2/3 HCV-infected patients (FISSION). J Hepatol 2013; 58(Suppl. 1): S3. 32. Nelson DR, Feld J, Kowdley KV, et al. All oral therapy with Sofosbuvir + ribavirin for 12 or 16 weeks in treatment experienced GT 2/3 HCV-infected patients: results of the phase 3 FUSION trial. J Hepatol 2013; 58(Suppl. 1): S3–4. 33. Lawitz E, Ghalib R, Rodriguez-Torres M, et al. Suppression of viral load through 4 week post-treatment results of a once-daily regimen of Simeprevir+Sofosbuvir with or without ribavirin in hepatitis C virus GT 1 null respond-

Liver International (2014) © 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd

Treatment of HCV genotype 3

34.

35.

36.

37.

38.

39.

ers. 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013). Atlanta, March 3-6 2013. Abstract 155LB. Lawitz E, Poordad F, Pang P, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an openlabel, randomised, phase 2 trial. Lancet 2013; doi: 10.1016/ S0140-6736(13)62121-2 [Epub ahead of print]. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Sustained virologic response with Daclatasvir plus Sofosbuvir +/- ribavirin (RBV) in chronic HCV genotype (GT) 1 -infected patients who previously failed Telaprevir (TVR) or Boceprevir (BOC). J Hepatol 2013; 58(Suppl. 1): S570. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. High rate of sustained virologic response with the all-oral Combination of Daclatasvir (NS5A inhibitor) plus Sofosbuvir (nucleotide NS5B inhibitor), with or without ribavirin, in treatment-na€ıve patients chronically infected with HCV genotype 1, 2, or 3. 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2012). Boston, November 9-13, 2012. Abstract LB-02. Kowdley KV, Lawitz E, Poordad F, et al. A 12-week interferon-free treatment regimen with ABT 450/r, ABT-267, ABT-333, and ribavirin achieves SVR12 rates (observed data) of 99% in treatment na€ıve patients and 93% in prior null responders in HCV genotype 1 infection. 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2012). Boston, November 9-13, 2012. Abstract LB-01. Everson GT, Sims KD, Rodriguez-Torres M, et al. An Interferon-free, Ribavirin-free 12-Week Regimen of Daclatasvir (DCV), Asunaprevir (ASV), and BMS-791325 Yielded SVR4 of 94% in Treatment-Naive Patients with Genotype (GT) 1 Chronic Hepatitis C Virus (HCV) Infection. 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2012). Boston, November 9-13, 2012. Abstract LB-3. Pawlotsky JM, Sarin SK, Foster G, et al. Alisporivir plus ribavirin is highly effective as interferon-free or interferonadd-on regimen in previously untreated HCV-GT2 or GT3 patients: SVR12 results from VITAL-1 phase 2b study. J Hepatol 2012; 56(Suppl. 2): S553.

23

Treatment of hepatitis C virus genotype 3-infection.

The treatment of hepatitis C virus (HCV) infection with pegylated interferon (PEG-IFN) alfa and ribavirin (800 mg daily) (RBV) is the standard of care...
318KB Sizes 0 Downloads 0 Views